News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
NIH-OTT authors report in Nature Biotechnology (Jan 2014) an analysis of FDA approved drugs and biologics that utilize inventions licensed from the NIH Intramural Research Program (IRP). Compared with other public-sector research institutions in the US, the NIH-IRP contribution has had a
The Office of Intramural Research, Office of the Director, NIH, invites you to the eighth annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer. The lecture will be held on Friday, November 22, 2013, at 10:00 AM in the Lipsett Amphitheatre, Building 10, NIH
CRADA collaboration opportunities are being offered by the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) to facilitate the development of small molecule compounds early in the development cycle. Both collaborations will focus on